Search

Your search keyword '"Cashen, Amanda"' showing total 1,045 results

Search Constraints

Start Over You searched for: Author "Cashen, Amanda" Remove constraint Author: "Cashen, Amanda"
1,045 results on '"Cashen, Amanda"'

Search Results

1. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

3. KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress

5. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

6. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

8. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

9. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

10. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

11. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

12. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

13. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

14. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

15. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

16. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis

17. Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.

18. Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT

19. Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma

21. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

23. A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma

25. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

27. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

28. Supplementary Figure 5 from Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

29. 74. Genomic analyses of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common clonal origin

32. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)

34. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

35. A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

36. TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT)

37. POSTER: TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT)

38. P1182: A PROSPECTIVE STUDY OF TCR MEASURABLE RESIDUAL DISEASE IN PERIPHERAL T-CELL LYMPHOMA

39. P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

40. PB2498: A PHASE 1 STUDY OF WU-NK-101 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

44. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

45. Immunophenotypic Variations in Mantle Cell Lymphoma and Their Impact on Clinical Behavior and Outcome

46. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

47. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

48. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

49. Brief IL-12, IL-15, IL-18 activation drives the acquisition of two distinct memory-like NK cell states

50. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Catalog

Books, media, physical & digital resources